Gianvi
NDC Package 54868-6162-0

11-digit billing NDC: 54868616200

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Gianvi is ™ (drospirenone and ethinyl estradiol tablets) 3 mg/0.02 mg is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.Oral contraceptives are highly effective. Marketed by Physicians Total Care, Inc., this product is identified by NDC 54868-6162 and is authorized under FDA application ANDA078515.

Identification & Billing

NDC Package Code
54868-6162-0
Package Description
1 KIT in 1 BLISTER PACK
Product Code
11-Digit Billing Format
54868616200
RxNorm Crosswalk
  • RxCUI: 630734 - drospirenone 3 MG / ethinyl estradiol 0.02 MG Oral Tablet
  • RxCUI: 748797 - inert 1 MG Oral Tablet
  • RxCUI: 748797 - inert ingredients 1 MG Oral Tablet
  • RxCUI: 748798 - {24 (drospirenone 3 MG / ethinyl estradiol 0.02 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack
  • RxCUI: 748798 - Drospiren-Eth estra 3-0.02 MG (24) Oral Tablet / Inert 1 MG (4) Oral Tablet 28 Day Pack

Clinical Specifications

Proprietary Name
Gianvi
Dosage Form
-
Usage Information
Gianvi™ (drospirenone and ethinyl estradiol tablets) 3 mg/0.02 mg is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.Oral contraceptives are highly effective. Table II lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and contraceptive implants and IUDs, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.Gianvi™ (drospirenone and ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Gianvi™ (drospirenone and ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control.TABLE II: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR: UNITED STATES.    % of Women Experiencing an Unintended Pregnancy Within the First Year of Use% of Women Continuing Use at One YearMethod (1) Typical Use  (2)Perfect Use  (3)(4)Chance  858540Spermicides  26663Periodic abstinence 25 Calendar 9 Ovulation method 3Sympto-thermal 2Post-ovulation 1Withdrawal 194CapWith spermicidal cream or jelly. Parous women 402642 Nulliparous women 20956Sponge Parous women 402042 Nulliparous women 20956Diaphragm20656Condom  Female (Reality) 21556 Male 14361Pill 571 progestin only 0.5 combined 0.1IUD Progesterone T 21.581 Copper T 380A 0.80.678 Lng 20 0.10.181Depo Provera 0.30.370Norplant and Norplant-2 0.050.0588Female sterilization 0.50.5100Male sterilization 0.150.1100Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998.

Regulatory & Marketing

Labeler Name
Physicians Total Care, Inc.
FDA Application #
ANDA078515
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-21-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 54868-6162-0 identifies a specific commercial package of 1 kit in 1 blister pack of Gianvi, labeled by Physicians Total Care, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Physicians Total Care, Inc. on October 21, 2010. The current certification is valid through December 31, 2017.

How is this Physicians Total Care, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 54868616200. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
54868-6162-0
11-Digit CMS (5-4-2)
54868-6162-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.